| Nov 18 |
Nektar Therapeutics Presents First Preclinical Data from Novel CSF-1 Program, NKTR-422, at 2024 American College of Rheumatology (ACR) Convergence
|
| Nov 14 |
Multiple Catalysts Ahead For Nektar Therapeutics
|
| Nov 10 |
Nektar Therapeutics (NASDAQ:NKTR) Just Reported And Analysts Have Been Lifting Their Price Targets
|
| Nov 9 |
Nektar Therapeutics Third Quarter 2024 Earnings: Beats Expectations
|
| Nov 8 |
Nektar Q3 Loss Narrower Than Expected, Pipeline Development in Focus
|
| Nov 8 |
Nektar Therapeutics (NKTR) Q3 2024 Earnings Call Highlights: Strategic Moves and Financial Outlook
|
| Nov 8 |
Nektar Therapeutics (NKTR) Q3 2024 Earnings Call Transcript
|
| Nov 7 |
Nektar Therapeutics (NKTR) Reports Q3 Loss, Tops Revenue Estimates
|
| Nov 7 |
Nektar: Q3 Earnings Snapshot
|
| Nov 7 |
Nektar Therapeutics GAAP EPS of -$0.18 beats by $0.03, revenue of $24.12M beats by $5.84M
|
